{"disease":{"id":"paroxysmal-nocturnal-hemoglobinuria-pnh","name":"paroxysmal nocturnal hemoglobinuria pnh"},"drugs":{"marketed":[{"drug_id":"eculizumab-aeeb","indication_name":"Paroxysmal Nocturnal Hemoglobinuria (PNH)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BKEMV","generic_name":"ECULIZUMAB-AEEB","company_name":"AMGEN INC","drug_phase":"marketed","molecular_target":"","drug_class":"Complement Inhibitor [EPC]","quality_score":20,"revenue":null,"mechanism":""},{"drug_id":"crovalimab","indication_name":"paroxysmal nocturnal hemoglobinuria (PNH)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Piasky","generic_name":"CROVALIMAB","company_name":"Genentech Inc","drug_phase":"marketed","molecular_target":"","drug_class":"Complement C5 Inhibitor [EPC]","quality_score":62,"revenue":null,"mechanism":"Piasky works by blocking the action of the Complement C5 protein, which is involved in the immune system's response to foreign substances."}],"pipeline":[],"offLabel":[],"totalMarketed":2,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04645199","title":"National Longitudinal Cohort of Hematological Diseases","phase":"","overall_status":"RECRUITING","enrollment_count":2300,"lead_sponsor_name":"Institute of Hematology & Blood Diseases Hospital, China","has_results":false},{"nct_id":"NCT02946463","title":"ALXN1210 (Ravulizumab) Versus Eculizumab in Complement Inhibitor Treatment-Naïve Adult Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":272,"lead_sponsor_name":"Alexion Pharmaceuticals, Inc.","has_results":true},{"nct_id":"NCT03056040","title":"ALXN1210 Versus Eculizumab in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Eculizumab","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":202,"lead_sponsor_name":"Alexion Pharmaceuticals, Inc.","has_results":true},{"nct_id":"NCT06933914","title":"Long-term Safety and Tolerability of MY008211A Tablets in Patients With Paroxysmal Nocturnal Hemoglobinuria","phase":"PHASE2, PHASE3","overall_status":"RECRUITING","enrollment_count":120,"lead_sponsor_name":"Wuhan Createrna Science and Technology Co., Ltd","has_results":false},{"nct_id":"NCT04558918","title":"Study of Efficacy and Safety of Twice Daily Oral LNP023 in Adult PNH Patients With Residual Anemia Despite Anti-C5 Antibody Treatment","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":97,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT06312644","title":"Study of Ultomiris® (Ravulizumab) Safety in Pregnancy","phase":"","overall_status":"RECRUITING","enrollment_count":75,"lead_sponsor_name":"Alexion Pharmaceuticals, Inc.","has_results":false},{"nct_id":"NCT06294301","title":"A Study of Single and Multiple Doses of LP-005 in Healthy Adult Participants","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":68,"lead_sponsor_name":"Longbio Pharma","has_results":false},{"nct_id":"NCT03520647","title":"Haplo-identical Transplantation for Severe Aplastic Anemia, Hypo-plastic MDS and PNH Using Peripheral Blood Stem Cells and Post-transplant Cyclophosphamide for GVHD Prophylaxis","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":56,"lead_sponsor_name":"National Heart, Lung, and Blood Institute (NHLBI)","has_results":false},{"nct_id":"NCT07229235","title":"REAL-CARE: Real-world Effectiveness of Iptacopan in Italian Patients With Paroxysmal Nocturnal Hemoglobinuria","phase":"","overall_status":"RECRUITING","enrollment_count":50,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT05876312","title":"Safety, Tolerability, PK and PD of ADX-038 in Healthy Participants and Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":50,"lead_sponsor_name":"ADARx Pharmaceuticals, Inc.","has_results":false},{"nct_id":"NCT06561841","title":"A Study to Evaluate the Efficacy and Safety of HSK39297 in Patients With Paroxysmal Nocturnal Hemoglobinuria（PNH）","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":47,"lead_sponsor_name":"Haisco Pharmaceutical Group Co., Ltd.","has_results":false},{"nct_id":"NCT04820530","title":"Study of Efficacy and Safety of Twice Daily Oral Iptacopan (LNP023) in Adult PNH Patients Who Are Naive to Complement Inhibitor Therapy","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":40,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT04170023","title":"Study of the Oral Factor D (FD) Inhibitor ALXN2050 in PNH Patients as Monotherapy","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":29,"lead_sponsor_name":"Alexion Pharmaceuticals, Inc.","has_results":true},{"nct_id":"NCT03078582","title":"Phase 2 Safety and Efficacy Study of Zilucoplan (RA101495) to Treat PNH Patients","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":26,"lead_sponsor_name":"Ra Pharmaceuticals","has_results":true},{"nct_id":"NCT07187401","title":"A First-in-Human Safety and Efficacy Study of ALN-CFB, a Small Interfering RNA (siRNA) Targeting Complement Factor B, in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria With Persistent Anemia on a C5 Inhibitor","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":24,"lead_sponsor_name":"Regeneron Pharmaceuticals","has_results":false},{"nct_id":"NCT03946748","title":"Study to Evaluate the Efficacy and Safety of REGN3918 in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":24,"lead_sponsor_name":"Regeneron Pharmaceuticals","has_results":true},{"nct_id":"NCT06987864","title":"An Extension Clinical Study of BCD-148 for the Treatment of Patients With PNH Previously Treated in Clinical Study No. BCD-148-2/NOCTURN","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":24,"lead_sponsor_name":"Biocad","has_results":false},{"nct_id":"NCT03225287","title":"Extension Study of RA101495 for Patients With PNH Who Have Completed a Zilucoplan (RA101495) Clinical Study","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":19,"lead_sponsor_name":"Ra Pharmaceuticals, Inc.","has_results":true},{"nct_id":"NCT03439839","title":"Study of Safety, Efficacy, Tolerability, Pharmacokinetics and Pharmacodynamics of LNP023 in in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":16,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT05116787","title":"BCX9930 for the Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) in Participants Not Receiving Other Complement Inhibitor Therapy","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":12,"lead_sponsor_name":"BioCryst Pharmaceuticals","has_results":true},{"nct_id":"NCT03472885","title":"Study of Danicopan in Participants With Paroxysmal Nocturnal Hemoglobinuria With Inadequate Response to Eculizumab","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":12,"lead_sponsor_name":"Alexion Pharmaceuticals, Inc.","has_results":true},{"nct_id":"NCT06934967","title":"Study to Assess the Pharmacokinetics, Safety, and Tolerability of Iptacopan in Pediatric PNH Patients","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":12,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT05116774","title":"BCX9930 for the Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) in Participants With Inadequate Response to C5 Inhibitor Therapy","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":12,"lead_sponsor_name":"BioCryst Pharmaceuticals","has_results":true},{"nct_id":"NCT03053102","title":"Study of Danicopan in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":10,"lead_sponsor_name":"Alexion Pharmaceuticals, Inc.","has_results":true},{"nct_id":"NCT07387302","title":"SLN12140 in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) in China","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":10,"lead_sponsor_name":"Linno Pharmaceuticals, Inc.","has_results":false},{"nct_id":"NCT03588026","title":"Treating Paroxysmal Nocturnal Haemoglobinuria Patients With rVA576","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":9,"lead_sponsor_name":"AKARI Therapeutics","has_results":false},{"nct_id":"NCT02264639","title":"A Phase I Study to Assess the Safety of Pegcetacoplan (APL-2) as an Add-On to Standard of Care in Subjects With PNH","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":9,"lead_sponsor_name":"Apellis Pharmaceuticals, Inc.","has_results":true},{"nct_id":"NCT06852092","title":"Study on Mass Balance of [14C]HSK39297 in Healthy Chinese Adult Male Subjects","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":7,"lead_sponsor_name":"Haisco Pharmaceutical Group Co., Ltd.","has_results":false},{"nct_id":"NCT03030183","title":"Phase 2 Safety and Efficacy Study of Zilucoplan (RA101495) to Treat PNH Patients Who Have an Inadequate Response to Eculizumab","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":3,"lead_sponsor_name":"Ra Pharmaceuticals","has_results":true},{"nct_id":"NCT03427060","title":"Coversin in PNH in Patients With Resistance to Eculizumab Due to Complement C5 Polymorphisms","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":1,"lead_sponsor_name":"AKARI Therapeutics","has_results":true},{"nct_id":"NCT05222412","title":"Managed Access Programs for LNP023, Iptacopan","phase":"","overall_status":"AVAILABLE","enrollment_count":null,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false}],"total":31},"guidelines":[],"source":"Drug Landscape verified database"}